← All deals

Thetis Pharmaceuticals LLC

PharmaceuticalsPharmaceuticalsBiotechTherapeutics
📍 Ridgefield, CT, United States• Founded 2011
StreetZero Signal 60
Be the first to signal interest

About Thetis Pharmaceuticals LLC

Thetis Pharmaceuticals is a biopharmaceutical company focused on developing first-in-class small molecule therapies for autoimmune diseases and cancer, including TP-317 as an oral therapy for Crohn’s disease. It leverages its proprietary HEALER™ technology platform to enable pharmaceutical development of specialized pro-resolving mediators. The company is based in Ridgefield, CT and has received funding from institutions including the Helmsley Charitable Trust, NIH, and Connecticut Innovations.

LATEST FUNDINGPrivate Placement
$560K
Announced 2026-10-13
TOTAL RAISED$19.6M
🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Thetis Pharmaceuticals LLC.

Free plan includes 3 full deal profiles every month.

Key highlights

  • Secured $4.2 million non-dilutive financing from Helmsley Charitable Trust in 2022 to advance TP-317 for Crohn’s disease.
  • Total funding reached $19.6M across 10 rounds including grants and loans from philanthropic and government sources.
  • Developing first-in-class resolvin-based oral therapy using proprietary HEALER technology platform.
  • Backed by multiple institutions focused on inflammatory bowel disease and resolution biology research.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account